Generic Ozempic: Is There a Generic Semaglutide or Wegovy in 2026?
No, there is no generic Ozempic, generic Wegovy, or generic semaglutide for sale in the United States. Semaglutide is the generic name of all three Novo Nordisk brands, but the compound patent that matters runs to December 5, 2031 and the formulation patents to 2041, according to the FDA Orange Book. Canada has approved three generics since April 2026. In the US, what you can buy today is brand semaglutide from $199/month through NovoCare, or compounded semaglutide from $69/month through tracked telehealth providers.
Quick Answer: Is There a Generic Ozempic?
There is no generic Ozempic in the United States in 2026. Ozempic's generic name is semaglutide, but Novo Nordisk's semaglutide compound patent (US 8,129,343) is listed by the FDA as expiring December 5, 2031, so no generic can be approved before then unless a challenger wins in court. The realistic price paths right now are brand Ozempic at $998/month list, NovoCare self-pay pens at $199–$499/month by dose, Ozempic tablets at $149–$299, about $25/month with a covering commercial plan and the savings card, or compounded semaglutide from $69/month (Embody and SnagRx). Across the 44 providers in our GLP-1 Price Index, the median compounded semaglutide price is $145/month (snapshot October 5, 2026).
Generic Ozempic at a Glance
Four numbers explain the generic-Ozempic question: when the compound patent expires, what the brand costs, what Novo Nordisk charges when you pay cash directly, and the compounded floor.
Patent dates are the FDA Orange Book listings for Ozempic (NDA 209637), Wegovy (NDA 215256) and Rybelsus (NDA 213051), read September 24, 2026. Brand prices are Novo Nordisk's list and NovoCare self-pay prices as tracked on our Ozempic cost and Wegovy cost pages. Compounded prices are each tracked provider's advertised monthly price as of October 5, 2026.
What Is the Generic Name for Ozempic, Wegovy and Rybelsus?
The generic name for Ozempic, Wegovy and Rybelsus is semaglutide. Ozempic is Novo Nordisk's once-weekly injection approved for type 2 diabetes on December 5, 2017; Wegovy is the same molecule at higher doses approved for chronic weight management, as an injection and, since December 2025, a daily tablet; Rybelsus is the original daily tablet for diabetes. All three are covered by the same core patent.
“Generic name” and “generic drug” are not the same thing, and the confusion drives most searches for generic Ozempic. Every medicine has a non-proprietary name (semaglutide, tirzepatide, ibuprofen). A generic drug is a separate product, approved by the FDA as equivalent to the brand and sold by another manufacturer once the brand's patents and exclusivities end. Semaglutide has a generic name but, in the United States, no generic drug. Anyone selling “generic Ozempic” to US patients is selling compounded semaglutide (legal under specific rules, not FDA-approved as a product), a Canadian or overseas product not approved for the US market, or something else entirely.
Why There Is No Generic Ozempic or Wegovy: The Patents, With Dates
The FDA Orange Book lists two semaglutide compound patents. The first, US 8,536,122, expired on March 20, 2026, which is why headlines said semaglutide was “going off patent” this year. The second, US 8,129,343, covers the same drug substance and runs to December 5, 2031, and it is the one that still blocks a generic. Behind it sit formulation patents to 2038 and 2041 that a generic maker must design around or challenge.
Source: FDA Orange Book patent listings for Ozempic (NDA 209637), Wegovy (NDA 215256) and Rybelsus (NDA 213051), via the Orange Book data files (September 2026 edition), read September 24, 2026. Ozempic also lists nine pen-device patents that expired between January and August 2026 and two more that expire February 27 and September 29, 2027; they are omitted below. The Orange Book itself warns that listings do not define the full range of claims a patent holder may assert.
| US patent | Expires | What it covers | Listed for |
|---|---|---|---|
| 8,536,122 | Mar 20, 2026 | Semaglutide drug substance + product (expired) | Ozempic · Wegovy · Rybelsus |
| 8,129,343 | Dec 5, 2031 | Semaglutide drug substance + product — the patent that still blocks a generic | Ozempic · Wegovy · Rybelsus |
| 9,132,239 | Feb 1, 2032 | Drug product (pen) | Ozempic |
| 10,335,462 | Jun 21, 2033 | Drug product + method of use | Ozempic |
| 9,764,003 | Jun 21, 2033 | Method of use | Wegovy |
| 12,239,739 | May 2, 2034 | Drug substance + product (oral) | Rybelsus |
| 12,569,543 | Apr 28, 2037 | Method of use | Ozempic · Wegovy |
| 10,888,605 · 11,752,198 · 12,214,017 | Aug 24, 2038 | Drug product (formulation) | Ozempic · Wegovy |
| 12,295,988 · 12,029,779 · 12,551,536 | Oct 10, 2038 | Method of use | Ozempic · Wegovy |
| 11,833,248 · 12,396,953 | Feb 1, 2039 | Drug product (oral formulation) | Rybelsus |
| 11,478,533 | May 13, 2040 | Method of use | Wegovy |
| 11,318,191 | Feb 17, 2041 | Drug product (formulation) | Ozempic · Wegovy |
FDA exclusivity is separate from patents
Semaglutide's five-year new-chemical-entity exclusivity ended on December 5, 2022, so the FDA can already accept generic applications; only patents stand in the way. What remains are three-year exclusivities tied to newer indications and strengths, which protect those specific uses rather than the molecule:
| Product | Exclusivity | Ends |
|---|---|---|
| Wegovy | I-935 — New indication exclusivity (3 years) | Mar 8, 2027 |
| Ozempic | I-961 — New indication exclusivity (3 years) | Jan 28, 2028 |
| Wegovy | I-973 — New indication exclusivity (3 years) | Aug 15, 2028 |
| Rybelsus | I-976 — New indication exclusivity (3 years) | Oct 17, 2028 |
| Wegovy 7.2 mg | NS — New strength exclusivity (3 years from the Mar 19, 2026 approval) | Mar 19, 2029 |
Exclusivity codes and durations per the FDA's Frequently Asked Questions on Patents and Exclusivity (NCE = 5 years; new indication and new strength = 3 years).
When Will Ozempic Go Generic?
Ozempic will not go generic in the United States before December 5, 2031, when Novo Nordisk's semaglutide compound patent (US 8,129,343) expires; the formulation patents behind it run to February 17, 2041. The milestones below are the ones that actually gate a US generic, in order; the Canadian approvals are included because they are what most “generic Ozempic” news in 2026 is about.
The first semaglutide patent (US 8,536,122) expired
The March 20, 2026 expiry of US 8,536,122 changed nothing for US patients: the second compound patent, US 8,129,343, covers the same drug substance until December 5, 2031.
Canada approves three generic semaglutides
Health Canada approved Dr. Reddy's generic Ozempic on April 28, 2026, Apotex's generic Ozempic on May 1, 2026, and Apotex's Sevmia, a generic Wegovy, on June 29, 2026, with six more submissions under review. They are approved for sale in Canada only.
The semaglutide compound patent (US 8,129,343) expires
December 5, 2031 is the earliest realistic date a generic semaglutide could reach US pharmacies, when Novo Nordisk's compound patent expires. A generic would still need FDA approval and a formulation that does not infringe the later patents.
Device, formulation and method-of-use patents expire
Ozempic's pen patent runs to February 1, 2032; formulation patents on Ozempic and Wegovy run to August 24, 2038 and February 17, 2041; Rybelsus's oral-formulation patents to May 2, 2034 and February 1, 2039. After these, nothing in the Orange Book stands in the way of a generic.
Two events could move a US generic semaglutide off the December 2031 date. A generic maker can file a “Paragraph IV” challenge arguing a patent is invalid or not infringed, which starts litigation Novo Nordisk has every incentive to fight and could bring the date forward. And Novo Nordisk keeps adding patents to the Orange Book as new ones issue: five of the Wegovy listings above were submitted in March and June 2026. We re-read the listings whenever this page is updated.
Is Generic Ozempic Available in Canada?
Yes. Canada became the first G7 country to approve a generic semaglutide on April 28, 2026, when Health Canada cleared Dr. Reddy's Laboratories' generic Ozempic for type 2 diabetes (Health Canada release). Apotex's generic Ozempic followed on May 1, 2026 (release), and on June 29, 2026 Health Canada approved Apotex's Sevmia, the first generic semaglutide for chronic weight management, the equivalent of Wegovy (release). Six further submissions were under review at that point. Health Canada notes that generic medicines in Canada typically cost 45 to 90% less than the brand.
Canada could act because Novo Nordisk's Canadian semaglutide patent lapsed, a situation specific to Canada. The US compound patent is intact until December 5, 2031, and the Canadian generics are approved for sale in Canada only, so they do not change what a US patient can buy at a US pharmacy.
Generic, Biosimilar, or Compounded: Which One Applies to Semaglutide?
A future US copy of semaglutide will be a generic (an ANDA), not a biosimilar, because Ozempic, Wegovy and Rybelsus are synthetic peptides approved under New Drug Applications, which the Orange Book lists as application type “N”, not biologics licensed under a BLA. Copies of NDA drugs go through the abbreviated new drug application (ANDA) pathway, the same route as generic ibuprofen; the biosimilar pathway is reserved for biologics licensed under a BLA. That matters for price: ANDA generics typically launch at steep discounts once several makers enter, which is consistent with the 45 to 90% figure Health Canada cites for Canadian generics.
Compounded semaglutide is neither. It is semaglutide prepared by a state-licensed 503A pharmacy or an FDA-registered 503B outsourcing facility for an individual prescription. It is not FDA-reviewed as a finished product, it is not “equivalent” in the regulatory sense, and the FDA has warned that unapproved GLP-1 products can carry dosing and quality risks (FDA: concerns with unapproved GLP-1 drugs used for weight loss). It is, however, the only semaglutide sold below the $149brand-tablet floor in the US, which is why it is what most “generic Ozempic” searches end up buying.
Is Compounded Semaglutide Still Legal Now That the Shortage Is Over?
Yes, under the standard patient-specific rules, but not as a mass-produced copy. The FDA declared the semaglutide shortage resolved on February 21, 2025 (declaratory order) and gave compounders a wind-down: state-licensed 503A pharmacies until April 22, 2025 and 503B outsourcing facilities until May 22, 2025 (FDA policy statement). Since then a pharmacy can no longer point to the shortage as its legal basis; a prescriber has to write a patient-specific prescription and a licensed pharmacy has to prepare it under the normal compounding rules, which is how the tracked providers below still offer it.
Practically, that means the provider you choose matters more than it did during the shortage. Every provider in our ladder is checked for a named, US-licensed pharmacy in our scoring methodology, and our scam checker flags the ones that hide it. 4 tracked providers in the ladder (Strut Health, Sprout Health, Direct Meds GLP-1, MEDVi) have received an FDA warning letter; the badge links to the letter so you can read it before you decide.
Brand Semaglutide Without a Generic: What Novo Nordisk Charges Directly
Novo Nordisk sells semaglutide to cash-paying US patients through NovoCare at a fraction of list price, which is the closest thing to a “generic” discount that exists for the FDA-approved product. These are the prices as read on NovoCare's pages on September 21, 2026.
| Product | List price | NovoCare self-pay | Other routes |
|---|---|---|---|
| Ozempic pen | $998/mo | $199 (0.25/0.5 mg) · $349 (1 mg) · $499 (2 mg) | Savings card: as little as $25/mo with covering commercial insurance (max $100/mo saving) |
| Ozempic tablets | — | $149 · $199 · $299 by dose | Self-pay only pricing shown |
| Wegovy pen | $1,349/mo | $199 first two fills (new patients, 0.25/0.5 mg, through Dec 31, 2026), then $349; 7.2 mg $399 | Medicare GLP-1 Bridge: $50/mo since July 1, 2026 |
| Wegovy pill | $1,349/mo | $149 (1.5 mg) · $199 (4 mg) · $299 (9 and 25 mg) | Medicare GLP-1 Bridge: $50/mo |
Sources: NovoCare Ozempic self-pay, Wegovy offer and Ozempic savings offer (pricing to be updated after December 31, 2026). Lilly's Foundayo, a different oral GLP-1 molecule, is $149–$299/month by dose and is covered in our Foundayo guide.
What “Generic Ozempic” Searches Actually Find: 18 Tracked Compounded Providers, Cheapest First
Advertised monthly price for compounded semaglutide on each provider's own site, verified for the October 5, 2026 Price Index snapshot. Only providers we track end-to-end are listed; plan terms differ and are spelled out row by row on Cheapest Semaglutide.
| # | Provider | Semaglutide / mo | vs Ozempic list | States | |
|---|---|---|---|---|---|
| 1 | Embody#1 pick | $69 | −93% | 48 | Visit Embody |
| 2 | SnagRx | $69 | −93% | 48 | Visit SnagRx |
| 3 | Trimi | $99 | −90% | 47 | Visit Trimi |
| 4 | Oak Longevity | $119 | −88% | 50 | Visit Oak Longevity |
| 5 | bmiMD | $119 | −88% | 48 | Visit bmiMD |
| 6 | Strut HealthFDA letter 2026 | $129 | −87% | 49 | Visit Strut Health |
| 7 | Bodybuilding.com Health+ | $141.50 | −86% | 47 | Visit BB Health+ |
| 8 | DudeMeds | $149 | −85% | 46 | Visit DudeMeds |
| 9 | TMates | $158 | −84% | 45 | Visit TMates |
| 10 | ShedRx | $159 | −84% | 50 | Visit ShedRx |
| 11 | TrimRx | $179 | −82% | 45 | Visit TrimRx |
| 12 | PlexusDx | $189 | −81% | 50 | Visit PlexusDx |
| 13 | Enhance MD | $212 | −79% | 50 | Visit Enhance MD |
| 14 | Wellorithm | $247 | −75% | 47 | Visit Wellorithm |
| 15 | Sprout HealthFDA letter 2025 | $249 | −75% | 50 | Visit Sprout Health |
| 16 | Direct Meds GLP-1FDA letter 2025 | $249 | −75% | 45 | Visit Direct Meds |
| 17 | Willow | $299 | −70% | 38 | Visit Willow |
| 18 | MEDViFDA letter 2026 | $299 | −70% | 49 | Visit MEDVi |
All 18 tracked semaglutide providers are shown, cheapest first. Some headline prices require an annual or multi-month plan; the compounded semaglutide guide covers pharmacy checks and plan terms.
GLP-1 Price Index: Semaglutide Market Snapshot (October 5, 2026)
The Index re-verifies every tracked provider's advertised price weekly on the provider's own site. Compounded semaglutide at $69/month is 14× cheaper than Ozempic's list price and about 65% below NovoCare's cheapest self-pay pen. Full history on the GLP-1 Price Index.
Does Waiting for a Generic Cost You Anything?
Yes: waiting for a generic Ozempic means paying brand prices until at least December 2031, while compounded semaglutide already delivers the same molecule from $69/month. The evidence for the molecule does not depend on the label: in the STEP 1 trial (NEJM 2021), adults without diabetes lost an average of 14.9% of body weight on semaglutide 2.4 mg over 68 weeks, against 2.4% on placebo. Brand Ozempic and Wegovy are the FDA-reviewed way to get that result; NovoCare self-pay from $199/month is the cheapest brand path without insurance, and compounded semaglutide from $69/month is the cheapest path of all, with the trade-off that the finished product is not FDA-reviewed, so pharmacy quality carries the weight the FDA would otherwise carry.
If you have commercial insurance that covers Ozempic or Wegovy, the Novo Nordisk savings card can bring the copay to as little as $25/month; if you are on Medicare Part D, the GLP-1 Bridge Program has covered Wegovy at $50/month since July 1, 2026. Both are cheaper than any compounded option and are the first things to check. See Ozempic cost, Wegovy cost and Medicare GLP-1 coverage for eligibility.
Generic Ozempic FAQ
Is there a generic Ozempic?
+
No, as of October 2026 there is no FDA-approved generic Ozempic or generic semaglutide in the United States. Novo Nordisk's semaglutide compound patent (US 8,129,343) is listed in the FDA Orange Book with a December 5, 2031 expiration, and its formulation patents run to August 2038 and February 2041, so a US generic is not expected before December 5, 2031. Canada approved its first generic semaglutide on April 28, 2026, but those products are approved for sale in Canada only.
What is the generic name for Ozempic?
+
The generic name for Ozempic is semaglutide. Ozempic is Novo Nordisk's brand of once-weekly injectable semaglutide approved for type 2 diabetes (FDA-approved December 5, 2017). The same molecule is sold as Wegovy for weight management and as Rybelsus tablets for diabetes. "Generic name" and "generic drug" are different things: semaglutide is the non-proprietary name, but no generic-drug version is approved in the US.
What is the generic name for Wegovy?
+
The generic name for Wegovy is semaglutide, the same molecule as Ozempic and Rybelsus. Wegovy is the brand approved for chronic weight management (injection, and since December 2025 a daily tablet), Ozempic is the brand approved for type 2 diabetes, and Rybelsus is the original oral tablet for diabetes. There is no generic-drug version of Wegovy in the United States.
Is there a generic for Wegovy?
+
No. There is no generic for Wegovy in the US. The Orange Book lists the semaglutide compound patent (US 8,129,343) as expiring December 5, 2031 for Wegovy, with formulation patents to August 24, 2038 and February 17, 2041 and a method-of-use patent to May 13, 2040. Canada approved a generic Wegovy (Apotex's Sevmia) on June 29, 2026. In the US, the cheapest ways to get Wegovy are NovoCare self-pay (pen $199 for the first two fills then $349; pill $149–$299 by dose), $50/month through Medicare's GLP-1 Bridge Program, or compounded semaglutide from $69/month.
When will Ozempic go generic?
+
Ozempic is not expected to go generic in the United States before December 5, 2031, when Novo Nordisk's semaglutide compound patent expires. An earlier semaglutide patent (US 8,536,122) expired on March 20, 2026, and a cluster of pen-device patents expired between January and August 2026, but the '343 compound patent and formulation patents running to 2038–2041 still block a generic. A generic maker could launch earlier only by winning a patent challenge in court. Novo Nordisk's regulatory exclusivities are shorter and end between 2027 and 2029.
How much does generic Ozempic cost?
+
There is no generic Ozempic price in the US because no generic exists. What "generic Ozempic" searches actually find is compounded semaglutide, which tracked telehealth providers sell for $69–$299/month (Embody and SnagRx at $69; median $145 across the 44 providers in the GLP-1 Watchdog Price Index, snapshot October 5, 2026). Brand Ozempic lists at $998/month; NovoCare sells self-pay Ozempic pens for $199, $349 and $499/month by dose and Ozempic tablets for $149–$299. In Canada, Health Canada says generics typically cost 45 to 90% less than the brand.
Is compounded semaglutide the same as generic Ozempic?
+
No. A generic drug is FDA-approved through an abbreviated new drug application (ANDA) as equivalent to the brand. Compounded semaglutide is prepared by a state-licensed 503A pharmacy or FDA-registered 503B outsourcing facility for an individual prescription, is not FDA-reviewed as a finished product, and since the FDA declared the semaglutide shortage resolved on February 21, 2025 it can only be compounded under the standard patient-specific rules. It uses the same active molecule, which is why it sells for $69–$299/month instead of $998.
Is generic Ozempic available in Canada?
+
Yes. Health Canada approved Dr. Reddy's generic semaglutide for type 2 diabetes on April 28, 2026 (the first G7 approval), Apotex's generic Ozempic on May 1, 2026, and Apotex's Sevmia, the first generic semaglutide for weight management, on June 29, 2026, with six further submissions under review. Canada could approve them because Novo Nordisk's Canadian semaglutide patent lapsed, which does not apply in the United States, where the US compound patent runs to December 5, 2031. The Canadian generics are approved for sale in Canada only.
Is there a generic Rybelsus?
+
No. Rybelsus (oral semaglutide) shares the December 5, 2031 semaglutide compound patent with Ozempic and Wegovy, and its own oral-formulation patents run to May 2, 2034 and February 1, 2039 per the FDA Orange Book, so no generic Rybelsus is expected before December 5, 2031. Its new-indication exclusivity runs to October 17, 2028. The cheaper oral semaglutide options today are the Wegovy pill ($149–$299/month self-pay) and Ozempic tablets ($149–$299).
Sources & References
- FDA Orange Book — Ozempic (NDA 209637), Wegovy (NDA 215256), Rybelsus (NDA 213051) patent and exclusivity listings, and the Orange Book data files
- FDA — Frequently Asked Questions on Patents and Exclusivity
- FDA — Declaratory Order: Resolution of Shortages of Semaglutide Injection Products (February 21, 2025)
- FDA — FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize
- FDA — FDA's concerns with unapproved GLP-1 drugs used for weight loss
- Health Canada — Canada becomes the first G7 country to approve a generic version of semaglutide (April 28, 2026); second generic (May 1, 2026); first generic semaglutide for weight loss (June 29, 2026)
- Wilding JPH, et al. — Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1), NEJM 2021
- Novo Nordisk — NovoCare Ozempic self-pay, Wegovy self-pay offer and Ozempic savings offer (read September 21, 2026)